Stock Scorer

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. reported revenue of 41M USD for the quarter ending 30 June 2026, down 74.4% from 160M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 41M -74.4%
Operating Income Q2 '26 · ending 30 June 2026 -96M —
Net Income Q2 '26 · ending 30 June 2026 -91M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -119M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -119M —
Shares Outstanding Q2 '26 · ending 30 June 2026 126.1M +28.2%
EPS Q2 '26 · ending 30 June 2026 -3.91 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 247M-386M-353M-484M
20242024-12-31 258M-330M-283M-176M
20232023-12-31 117M-340M-307M-330M
20222022-12-31 112M-280M-267M432M
20212021-12-31 383M54M53M-282M
20202020-12-31 78M-124M-123M108M
20192019-12-31 15M-88.7M-84.7M-75.4M
20182018-12-31 8.4M-54.9M-49.6M-46.7M
20172017-12-31 1.4M-53.4M-53.1M-30.6M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3041M
Q1 '262026-03-3117M
Q4 '252025-12-3133M
Q3 '252025-09-3026M
Q2 '252025-06-30160M
Q1 '252025-03-3128M
Q4 '242024-12-3126M
Q3 '242024-09-3048M
Q2 '242024-06-3039M
Q1 '242024-03-31145M
Q4 '232023-12-3131M
Q3 '232023-09-3032M
Q2 '232023-06-3029M
Q1 '232023-03-3125M
Q4 '222022-12-3134M
Q3 '222022-09-3033M
Q2 '222022-06-3027M
Q1 '222022-03-3118M
Q4 '212021-12-31354.6M
Q3 '212021-09-309.5M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-96M
Q1 '262026-03-31-134M
Q4 '252025-12-31-114M
Q3 '252025-09-30-142M
Q2 '252025-06-30-8M
Q1 '252025-03-31-122M
Q4 '242024-12-31-103M
Q3 '242024-09-30-105M
Q2 '242024-06-30-106M
Q1 '242024-03-31-16M
Q4 '232023-12-31-91M
Q3 '232023-09-30-80M
Q2 '232023-06-30-83M
Q1 '232023-03-31-86M
Q4 '222022-12-31-74M
Q3 '222022-09-30-70M
Q2 '222022-06-30-69M
Q1 '222022-03-31-67M
Q4 '212021-12-31281M
Q3 '212021-09-30-78.1M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-91M
Q1 '262026-03-31-128M
Q4 '252025-12-31-106M
Q3 '252025-09-30-135M
Q2 '252025-06-300
Q1 '252025-03-31-112M
Q4 '242024-12-31-94M
Q3 '242024-09-30-92M
Q2 '242024-06-30-93M
Q1 '242024-03-31-4M
Q4 '232023-12-31-81M
Q3 '232023-09-30-71M
Q2 '232023-06-30-75M
Q1 '232023-03-31-80M
Q4 '222022-12-31-67M
Q3 '222022-09-30-65M
Q2 '222022-06-30-67M
Q1 '222022-03-31-68M
Q4 '212021-12-31279.5M
Q3 '212021-09-30-78M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-119M
Q1 '262026-03-31-138M
Q4 '252025-12-31-120M
Q3 '252025-09-30-97M
Q2 '252025-06-30-133M
Q1 '252025-03-31-132M
Q4 '242024-12-31-100M
Q3 '242024-09-3026M
Q2 '242024-06-30-94M
Q1 '242024-03-31-2M
Q4 '232023-12-31-88M
Q3 '232023-09-30-63M
Q2 '232023-06-30-57M
Q1 '232023-03-31-98M
Q4 '222022-12-31-70M
Q3 '222022-09-30-81M
Q2 '222022-06-30-65M
Q1 '222022-03-31654M
Q4 '212021-12-31-61.9M
Q3 '212021-09-30-53.8M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-119M
Q1 '262026-03-31-138M
Q4 '252025-12-31-121M
Q3 '252025-09-30-97M
Q2 '252025-06-30-133M
Q1 '252025-03-31-133M
Q4 '242024-12-31-101M
Q3 '242024-09-3025M
Q2 '242024-06-30-94M
Q1 '242024-03-31-6M
Q4 '232023-12-31-94M
Q3 '232023-09-30-73M
Q2 '232023-06-30-62M
Q1 '232023-03-31-101M
Q4 '222022-12-31-70M
Q3 '222022-09-30-83M
Q2 '222022-06-30-66M
Q1 '222022-03-31651M
Q4 '212021-12-31-70.4M
Q3 '212021-09-30-61.6M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30126.1M
Q1 '262026-03-31125.4M
Q3 '252025-09-30106.5M
Q2 '252025-06-30106.5M
Q1 '252025-03-3198.4M
Q3 '242024-09-3091.4M
Q2 '242024-06-3091.1M
Q1 '242024-03-3186.2M
Q3 '232023-09-3074.6M
Q2 '232023-06-3073.2M
Q1 '232023-03-3173M
Q3 '222022-09-3072.2M
Q2 '222022-06-3071.8M
Q1 '222022-03-3171.2M
Q3 '212021-09-3070.1M
Q4 '202020-12-3163.5M
Q3 '202020-09-3065.1M
Q2 '202020-06-3048.6M
Q1 '202020-03-3144.3M
Q3 '192019-09-3043.9M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-3.91
Q1 '262026-03-31-3.19
Q4 '252025-12-31-3.31
Q3 '252025-09-30-3.44
Q2 '252025-06-30-3.17
Q1 '252025-03-31-4.19
Q4 '242024-12-31-3.10
Q3 '242024-09-30-3.15
Q2 '242024-06-30-3.09
Q1 '242024-03-31-3.11
Q4 '232023-12-31-4.15
Q3 '232023-09-30-4.00
Q2 '232023-06-30-3.96
Q1 '232023-03-31-3.85
Q4 '222022-12-31-3.72
Q3 '222022-09-301.20
Q2 '222022-06-300.99
Q1 '222022-03-310.83
Q4 '212021-12-310.71
Q3 '212021-09-30-4.15